New Drug Lanifibranor Promising for NASH

New Drug Lanifibranor Promising for NASH

Lanifibranor, a first-in-class pan-peroxisome proliferator-activated receptor (PPAR) agonist, has shown promise in the treatment of nonalcoholic steatohepatitis (NASH), an aggressive function of nonalcoholic fatty liver illness with few treatment alternate choices. In a phase 2b, double-blind, randomized, placebo-controlled trial of…